The FDA granted fast track status to DB-1310, a HER3-targeting antibody-drug conjugate, for advanced nonsquamous non-small cell lung cancer.

Tagrisso with chemo significantly improved survival and progression-free outcomes versus Tagrisso alone in newly diagnosed ...

FURVENT is a global, pivotal 3 arm Phase 3 clinical trial of firmonertinib in first-line non-squamous locally advanced or metastatic NSCLC patients with exon 20 insertion mutations being conducted ...

The abstracts accepted for mini oral presentations include updated efficacy and safety data from the Phase 2b REZILIENT1 ...

Citation: Classifying EGFR mutations by structure offers better way to match non-small cell lung cancer patients to treatments (2021, September 15) retrieved 8 May 2025 from https://medicalxpress ...

Primary and co-occurring mutations were recorded for 11,619 patients. Of those, 67.1% had classical EGFR mutations, 30.8% had atypical EGFR mutations and 2.2% had both.

Researchers from The University of Texas MD Anderson Cancer Center have discovered that grouping epidermal growth factor receptor (EGFR) mutations by structure and function provide an accurate ...

UCLA Health researchers at the Jonsson Comprehensive Cancer Center have recently won a pair of grants worth in total nearly ...

Around the world, dozens of clinical trials are now recruiting people who have NSCLC with an EGFR mutation. But before enrolling in a trial, there’s a lot to think about.

The ORR for patients with solitary or compound uncommon EGFR mutations was 45.5% and 66.7%, respectively, while median PFS was 5.4 months and 9.8 months, ...

“EGFR is what we call a driver mutation,” he explains. “A driver is a gene that’s part of your normal cell but will turn off and on in response to outside stimuli. But because of a genetic ...

Most patients with NSCLC who have EGFR mutations have exon 19 deletion or mutation of the exon 21 L858R. However, about 10% of patients have other mutations, such as T790M and exon 20 insertions.